Background-The Rheumatology Informatics System for Effectiveness (RISE) is a national electronic medical record (EMR)-enabled registry. RISE passively collects data from EMRs of participating practices, provides advanced quality measurement and data analytic capacities, and fulfills national quality reporting requirements. Here we report the registry's architecture and initial data, and demonstrate how RISE is being used to improve the quality of care.
Conclusion-RISE provides critical infrastructure for improving the quality of care in rheumatology and is a unique data source to generate new knowledge. Data validation and mapping is ongoing and RISE is available to the research and clinical communities to advance rheumatology.
Healthcare in the United States is undergoing rapid change, and rheumatologists face significant challenges in adapting to new payment and delivery models, evolving certification requirements and the rapid implementation of electronic medical records (EMRs). As part of a strategic plan to address these challenges, the American College of Rheumatology has developed the Rheumatology Informatics System for Effectiveness (RISE). RISE is a novel EMR-enabled registry that passively extracts EMR data from individual practices, aggregates and analyzes these data centrally, and feeds this information back to clinicians as actionable data using a web-based interface. RISE aims to decrease the burden of data collection on practices, to streamline participation in federal quality programs, and to facilitate local rapid-cycle quality improvement by providing continuous performance feedback and benchmarking.
In 2014, RISE passed a critical milestone and was designated a federally Qualified Clinical Data Registry (QCDR). The American Taxpayer Relief Act established the QCDR quality reporting option, allowing physicians to submit data for the Physician Qualify Reporting System (PQRS) directly through registries (1) . Because data collected through QCDRs is meant to improve quality, there is a waiver of individual patient informed consent for registry data capture. All RISE data used for research is de-identified. Moreover, RISE can be used to fulfill a meaningful use objective measure (reporting to a special registry), and is being developed as a tool for maintenance of certification. As the transition to a value-based system of reimbursement advances in the United States, RISE will allow rheumatologists to track their performance on measures of quality of care and efficiency. RISE will also serve as an important tool for research in rheumatology.
In this paper, we present the informatics structure of RISE, provide an overview of the type of data currently available to advance rheumatology care and research, report early results on quality measures, and share our vision for the future of the registry.
METHODS

RISE informatics structure
RISE is an EMR-enabled registry that automatically extracts data from individual practices' EMRs on a scheduled basis and transfers these data to a central data warehouse. RISE has been constructed to minimize impact on practice workflow. No data entry into a separate database is required; instead, RISE collects data that is entered during the course of routine clinical care into the EMR. This is made possible through technology that uses a light weight connector, installed locally, to establish a connection between the practice and RISE (Figure 1 ). RISE can connect to most certified EMR systems in the United States; currently, the registry can map to over 30 different EMRs used by rheumatologists. Once an EMR is connected, the RISE data mapping team works to identify participating clinicians and their patients and creates an initial EMR data extract. Practices then spend 6-10+ hours validating data elements and quality measure performance data before moving into full production. This latter step allows RISE to customize data capture to the particular EMR configuration and workflow within each practice. Once data mapping is complete, further time commitment from practices will only be required if there are data aberrancies or new measures that require mapping.
Data contributed to RISE are cleaned and analyzed centrally and feed a performance dashboard. Rheumatologists can access their practice dashboard through a web-based interface, where they can view national benchmarks for quality measures, performance means across the registry, as well as practice and clinician-level performance. Participating practices can also run customized queries on their own patient population and perform basic data analyses. For example, practices can run a query to identify all patients with a specific diagnosis code or on a specific medication. These data can then be used for quality improvement activities or for local research purposes.
Privacy and waiver of informed consent
RISE is a federally Qualified Clinical Data Registry (QCDR). The QCDR framework was introduced for the Physician Quality Reporting System (PQRS) in 2014, and allows the collection of data without patient informed consent for the purpose of disease tracking and to foster improvement in the quality of care (1) . CMS has the ability to access Medicare patient data in RISE for quality reports through CMS oversight authority. For non-Medicare data, CMS may request the QCDR to mask the protected health information (PHI) when aggregate data is requested.
The Western Institutional Review Board (IRB) reviewed RISE and determined that because RISE is a quality improvement registry focused on healthcare delivery and on measuring and reporting data for clinical, practical or administrative uses, individual practices do not need IRB approval or patient consent to implement RISE. The RISE data extraction protocol is Health Insurance Portability and Accountability Act (HIPAA) compliant. When a patient's information is uploaded, PHI is stored separately. Any data used by third parties for research is de-identified and aggregated. However, participating practices can access their own PHI data and use this data for their clinical and quality improvement needs and for reporting quality measures to CMS.
Quality measures and reporting
As a QCDR, RISE helps practices report clinical quality data to the PQRS program. This reporting allows eligible professionals to avoid negative payment adjustments in 2017. In addition, submission of PQRS data through RISE also satisfies an objective of the Meaningful Use program: reporting to a specialized registry. By fulfilling this Meaningful Use objective, RISE helps practices further avoid reporting penalties.
Research data repository
In addition to quality measurement and reporting, RISE serves as a resource for research. Both structured data (laboratories, medications, problem lists) and unstructured data (i.e. text from clinical notes) from the EMR are available for analysis. Research requests undergo formal committee review for feasibility. The ACR has contracted with three data analytic centers (University of California at San Francisco, University of Alabama at Birmingham, and Duke University) with special expertise in large dataset analyses to execute RISE data requests. These centers will work with de-identified data extracts; any identified data, including text from clinical notes, will remain within the clinical data warehouse and will be analyzed centrally.
Analysis of initial data in RISE
We analyzed data in RISE from October 1, 2014 through September 30, 2015, including the characteristics of participating practices and patients. We examined both sociodemographic characteristics of patients (age, sex, race/ethnicity, insurance status and U.S. region) as well as clinical characteristics (smoking status, blood pressure, billing and problem list diagnoses as defined by International Classification of Diseases (ICD) codes, and medications).
All sociodemographic characteristics and clinical data were examined from the most recent clinical encounter. When querying diagnoses, we generated a list of ICD9 codes for common rheumatic diseases and calculated the frequency of these diagnoses at the last available clinical encounter. We did not require these diagnoses to be mutually exclusive; in other words, patients with two diagnoses are represented twice.
Because a key initial focus of the registry is rheumatoid arthritis (RA), we examined clinical data for the subset of patients with this diagnosis in further detail to demonstrate the type of data in RISE. First, we examined active medications at the end of the most recent RA clinical encounter, including all non-biologic DMARDs (methotrexate, hydroxychloroquine, leflunomide, sulfasalazine, azathioprine, minocycline, cyclosporine, cyclophosphamide, penicillamine and gold), as well as biologic and targeted synthetic DMARDs (etanercept, adalimumab, infliximab, golimumab, certolizumab, abatacept, anakinra, tocilizumab, rituximab, tofacitinib). To create these categories, we built algorithms that collated instances where a single drug (e.g. methotrexate) appeared more than once as an active medication. This meant removing duplicate prescriptions and also collapsing instances where two formulations of the same drug were listed.
Similarly, we built algorithms to create mutually exclusive categories for the biologic DMARDs. For example, we manually reviewed all records in which patients were listed as being on two TNF inhibiting biologic drugs (1.1% of records). We contacted a sample of practices to understand the workflows leading to these within-class duplicates. Reasons identified included incomplete medication reconciliation or clinicians routinely ordering more than one drug at time of initiation while waiting for insurance authorization. In these instances, we either looked into future encounters to see which drug persisted and selected only the persistent drug, or randomly sampled one of the drugs.
Among individuals in RISE, we also examined performance on selected quality measures, including those recently endorsed by the National Quality Forum, such as Rheumatoid arthritis: Assessment of Disease Activity (NQF 2523), Rheumatoid arthritis: Functional Status Assessment (NQF 2524), Rheumatoid arthritis: Tuberculosis Screening (NQF 2522), and Rheumatoid arthritis: Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (NQF 2525), as well as additional measures in the areas of drug safety (use of high-risk medications in the elderly), osteoporosis (screening and treatment), preventive health (tobacco use, obesity and blood pressure management), gout (monitoring and serum urate), and medication reconciliation. We assessed the number of times the recommended process of care was performed among the eligible denominator population to arrive at the average performance on each measure. A higher average denotes higher quality with the exception of the measures regarding high-risk prescribing in the elderly, in which a lower average denotes higher quality.
A complete list of the 2015 RISE measures is included in the Appendix. The measures are evaluated and updated annually.
RESULTS
As of September 30, 2015, there were 312 clinicians and 55 practices participating in RISE. Seventy two percent of clinicians were in a group practice, 21% were solo practitioners and 7% were part of a larger health system. Sociodemographic and clinical characteristics of the 239,302 patients are in Table 1 . A majority of patients were women (74.8%), 22.2% were racial/ethnic minorities, and most had commercial insurance (47.8%). Almost a third (29.6%) had Medicare health insurance. At their last clinical encounter, 10.4% of patients were smokers, and 14.6% were hypertensive (systolic blood pressure of >140 mmHg or a diastolic blood pressure of >90 mmHg).
In Table 2 , we list the diagnoses captured in RISE, as defined by ICD9 codes at the last clinical encounter. Among the diagnoses examined, osteoarthritis was the most prevalent (n=76,381), followed by RA (n=60,102). RISE also includes a significant number of individuals with other rheumatologic disorders, such as Sjögren's syndrome (n=15,841), systemic lupus erythematosus (n=13,940), dermatomyositis (n=1,129), and temporal arteritis (n=1,596). Less common conditions, such as relapsing polychondritis (n=886), Behcet's syndrome (n=301), and Takayasu disease (n=85) are also represented.
For the subset of individuals with ICD9 codes for RA (n=60,102), active medications at the last clinical encounter are listed in Table 3 . Only 9% were on no DMARD therapy. Thirtyfour percent of individuals were using a biologic or targeted synthetic DMARD (n=20,759), while 67% were using a non-biologic DMARD (n=40,272). Twenty three percent were on biologic DMARD monotherapy. As expected, methotrexate was the most commonly used DMARD (43.5%), followed by hydroxychloroquine (23.3%).
Performance on selected RISE quality measures is listed in Table 4 . For example, performance on Rheumatoid Arthritis: Assessment of Disease Activity (NQF 2523) was 55.2%. Among those satisfying this measure, the most commonly used outcome measures were RAPID3 (56.0%) and CDAI (36.9%), with fewer patients having SDAI (0.04%), DAS28 (3.8%), or PAS-II (3.2%) scores recorded in the EMR. For Rheumatoid Arthritis: Functional Status Assessment (NQF 2524), performance was 53.6% and a majority of practices used the RAPID3/MDHAQ (45.2% of scores reported in the EMR) or a version of the HAQ (original HAQ 38.5% or HAQII 3.3%). As is reflected in the medication data, 91.0% of patients met the criteria for Rheumatoid Arthritis; Disease Modifying Anti-Rheumatic Drug (NQF 2525). For Rheumatoid Arthritis: Tuberculosis Screening (NQF 2522), performance was 55.2%. Across all measures in Table 4 , performance was highest for a measure regarding medication reconciliation (96.8%) and lowest for serum urate monitoring in gout patients (31.0%).
Some information was missing for all variables, but the proportion of missing data was low for most sociodemographic data except for insurance status (19.3%). Work is ongoing to understand the accuracy of diagnosis codes and medications in RISE, with initial data suggesting very good specificity for RA and for DMARDs (2) . The extent of missingness as well as accuracy is expected to improve as mapping and validation procedures for RISE continue in the coming years.
DISCUSSION
Payment reform, a proliferation of new medication options, and the widespread introduction of EMRs are transforming the practice of rheumatology in the United States. Given these changes, the ACR launched the RISE registry to help rheumatologists succeed in advancing the triple aim of improving the care experience, improving the health of populations and reducing the costs of care (3) . The enthusiastic participation of U.S. rheumatologists has allowed the registry to grow quickly since its launch in 2014.
RISE represents the first attempt to create a national EMR-enabled rheumatology registry in the United States, thereby avoiding separate entry of data by clinicians or office staff. The registry has made headway in addressing some of the challenges of interoperability that have previously made data sharing across health systems difficult. This is because RISE's clinical informatics structure was designed to be agnostic to the EMR system used by rheumatologists, and can be adapted to draw data from most certified systems. Central mapping of data also creates efficiencies for practices that have limited information technology support or data analytic software capabilities. Additionally, automation permits uploading of a clinician's entire population of patients, preventing biases in patient selection.
The data in RISE therefore provides a unique and inclusive view of rheumatology practices because patients with all medical conditions managed by rheumatologists and all types of insurance are included.
Initial data in RISE provide an interesting birds-eye view of the clinical characteristics of patients seen in participating rheumatology practices. Although prevalent rheumatologic conditions (e.g. osteoarthritis and rheumatoid arthritis) are well-represented in the registry, RISE already includes data on individuals with several less common conditions, such as inflammatory myopathies and vasculitides. As we try to improve the quality of rheumatologic care across these conditions, we anticipate that data on the natural history, treatment patterns and clinical outcomes on these disorders will make quality improvement efforts increasingly data-driven. Moreover, the generalizability of data in RISE is anticipated to improve as the registry grows and better reflects the racial/ethnic and geographic diversity of patients seen by rheumatologists.
In the area of RA, RISE has started to build a foundation for measuring and understanding outcomes, treatment patterns and also patient safety. Two nationally endorsed RISE electronic clinical quality measures (eCQMs), Rheumatoid Arthritis: Assessment of Disease Activity (NQF 2523) and Rheumatoid Arthritis: Functional Status Assessment (NQF 2524) are the first examples of EMR-enabled measures that collect outcomes, including patientreported outcomes, across the registry. We are encouraged by the fact that over one half of rheumatologists participating in RISE are routinely capturing this information in practice. Measurement of these outcomes using validated tools enables evidence-based care by facilitating a treat-to-target approach in RA, and also allows for tracking of outcomes and benchmarking across rheumatology practices. In addition, the considerable effort made by rheumatologists and their staff to collect this information in routine clinical care has resulted in one of the largest national efforts to collect patient-reported outcomes for a chronic disease via the EMR in the United States.
Another quality measure, Rheumatoid Arthritis: Disease Modifying Anti-Rheumatic Drug Therapy (NQF 2525), has created a foundation for ensuring that accurate information about medication utilization is collected across the registry. Not surprisingly, performance on this measure across rheumatology practices participating in RISE is high (91.0%). The data presented in this study demonstrate that RISE is capturing the full spectrum of medications used in RA. Work is ongoing to further refine and validate medication information, including initiation and discontinuation dates and ensuring that medications that may not be as reliably recorded in the EHR, such as infusible biologic DMARDs, are captured. In addition, Rheumatoid Arthritis: Tuberculosis Screening (NQF 2522) is an example of a patient safety measure. Our experience validating this measure suggests that lower performance on this measure indicates both a gap in quality and the fact that reliably capturing TB screening in practice requires further work to ensure accurate data capture (2) . Efforts are ongoing to improve mapping and further validate all quality measures in RISE.
For clinicians, RISE provides new opportunities to participate in efforts to improve the quality of care in rheumatology. Locally, the RISE user interface allows rheumatologists to track their performance on quality measures in conditions such as RA, gout and osteoporosis. RISE allows rheumatologists to not only participate in national quality reporting programs such as PQRS, but also provides critical data analytic capacity to facilitate rapid cycle quality improvement. Clinicians participating in RISE can run reports to view their performance on quality measures, and compare these data to others in their practice as well as against both the registry mean and national benchmarks. This marks a shift away from previous approaches to quality measurement, which have largely relied on administrative claims data or chart review. Limitations of claims data have included the lack of detailed clinical data and the sometimes significant delay in aggregating results; similarly, chart reviews required significant time investment which impeded rapid cycle quality involvement. By aggregating up-to-date EMR data and passively collecting more detailed clinical data, RISE is attempting to address some of these previous limitations.
In addition, as payers, particularly Medicare, increasingly tie payments to value assessments, there is an urgent need to develop measures to define "value" in rheumatology. The Medicare Access and CHIP Reauthorization Act (MACRA) of 2015 has put into place an aggressive timeline for a Merit-Based Incentive Payment System (MIPS) and for Alternative Payment Models (APMs). For rheumatologists to be successful under these payment reforms, it will be critical to generate both the measures and tools to capture the value of rheumatologic care in a meaningful way. Being able to develop, test and rapidly implement novel measures in RISE that define quality and efficiency will be critical. Understanding the scientific validity, feasibility, usefulness, and both intended and unintended consequences of these measures, are important strategic goals of RISE.
For researchers, RISE aims to generate data that can advance our understanding of the natural history, outcomes and treatment of rheumatologic disorders. Aggregated populationwide EMR data is a relatively new data source in the United States, and both management and analyses of these data will require rapid innovation in research methods and practices. First, RISE will include new types of data, including the text of clinical notes. Extracting information from this unstructured data will require developing new algorithms to identify variables of interest, using techniques such as text mining, natural language processing and machine learning. Second, although RISE's privacy and security framework is HIPAA compliant and research procedures have been approved by a national Institutional Review Board, addressing future threats to data security will require continuous vigilance and innovation. Third, data in RISE is observational in nature, and will accumulate rapidly. Analysis of "big data" will require new methods, including approaches to deal with missingness, censoring, non-uniform variables across a population, and evolving computational methods to recognize patterns in data such as machine learning. Moreover, changes in health data standards (e.g. implementation of ICD10) will require ongoing data integration and validation. Fourth, we anticipate that there will be interest in integrating RISE with other data sources and platforms, such as patient-powered networks, clinical trials networks, administrative claims data or disease-specific registries. Building the scientific and privacy frameworks to facilitate such integrations will also require significant collaboration, funding and innovation. In the near term, we hope that RISE will facilitate creating learning networks to share best practices and close gaps in quality of care.
In summary, the ACR has developed RISE to help rheumatologists leverage the new wave of big data from EMRs. By aggregating, analyzing and continuously feeding back data to rheumatology practices, RISE aims to advance our shared goals of improving knowledge about rheumatologic conditions, refining treatment strategies and outcomes, and improving the quality and safety of care. • RISE is a novel EMR-enabled registry that passively extracts EMR data from individual practices, aggregates and analyzes these data centrally, and feeds this information back to clinicians as actionable data for quality improvement using a web-based interface.
Quality measures in RISE.
Measure
• RISE's clinical informatics structure was designed to be agnostic to the EMR system used by rheumatologists, and can be adapted to draw data from most certified systems.
• Performance on quality measures across RISE practices presented here provides a useful benchmark for rheumatologists seeking to improve quality in their practices.
Figure 1. RISE Registry Data Flow for Practice Improvement and Research
The RISE registry uses a lightweight connector to establish a connection between a practice's EMR server and the centralized registry servers. Local practice data is iteratively mapped by the RISE team to ensure accuracy, and verified extracts enter the RISE Clinical Data Warehouse. Data are then aggregated and analyzed for federal quality reporting, research, and practice-based improvement. Authorized users in a practice can access the RISE data dashboard through a web-based registry portal. Table 3 Active medications among individuals with rheumatoid arthritis at the last clinical encounter in the RISE registry.
